Gilead Sciences, Inc.

Gilead Calistoga LLC

Musong Kim

Gary Bruce Phillips

Gayatri Balan

William John Watkins

Suet Chung Yeung

Kirk L Stevens

Joshua J Van Veldhuizen

John O Link

James G Taylor

Thorsten A Kirschberg

Nathan E Wright

Neil H Squires

Julian Andrew Codelli

Stephane Perreault

Jennifer Alissa Loyer-Drew

Jennifer Anne Treiberg

Joshua A Kaplan

Leena Patel

Chien-Hung Chou

Lafe J Purvis, Ii

Jeff A Zablocki

Scott A Mitchell

Jeromy J Cottell

Rao V Kalla

Elizabeth M Bacon

Thao Perry

Sheila M Zipfel

Scott D Schroeder

Seung H Lee

Jerry B Evarts

Zhimin Du

Christopher T Clark

Jayaraman Chandrasekhar

Jennifer R Lo

Mark J Bartlett

John H Conway

Patrick J Salvo

Jennifer Leigh Cosman

Shaopei Cai

Chandrasekar Venkataramani

Peter A Blomgren

Devan Naduthambi

Sundaramoorthi Swaminathan

Rhiannon Thomas-Tran

Marcin Stasiak

William Baker

Zachary A Kasun

Josh Van Veldhuizen

Michael T Tudesco

Barton W Phillips

Roland D Saito

Gregg M Schwarzwalder

Helen Yu

Chen Chen

Arthur Yeung

Dorothée Saddier Axe

Brian M Weist

Gary Phillips

Chienhung Chou

Jennifer L Cosman Ellis

Kirk K Stevens

Jennifer A Treiberg

Joshua Van Veldhuizen

Joshua Kaplan

Stephane Perrault

Lafe J Ii Purvis

Lafe J Purvis

Jerry Evarts

The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

IKAROS Zinc Finger Family degraders and uses thereof

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

Substituted 6-azabenzimidazole compounds

The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2, including cancer.

IKAROS zinc finger family degraders and uses thereof

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Cot modulators and methods of use thereof

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A', B&#x2032;, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Phosphatidylinositol 3-kinase inhibitors

COT modulators and methods of use thereof

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A', W, W, W, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Growing community of inventors

Bothell, WA, United States of America

Musong Kim